Sort
21,281 grants matching “influenza”
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
$1,855,534Ruth Margrit Ruprecht · University Of Louisiana At Lafayette · U19 · FY2020 · AI
T Cell Memory to Pathogens: Generation and Function
$1,853,585Susan L Swain · Univ Of Massachusetts Med Sch Worcester · P01 · FY2011 · AI
Live attenuated vaccines for epidemic and pandemic flu
$1,846,896Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · U01 · FY2007 · AI
CEIRS Influenza Data Processing and Coordinating Center (DPCC)
$1,846,788Gillian Air · Digital Infuzion, Inc. · N01 · FY2015 · AI
Adjuvant Discovery for Vaccines against Influenza Virus
$1,843,527Ofer Levy · Boston Children'S Hospital · N01 · FY2017 · AI
A deep longitudinal analysis of next generation influenza vaccines in older adults
$1,843,486Duygu Ucar · Jackson Laboratory · U01 · FY2025 · AI
Rapid point-of-care diagnostic for bioterrorism "A" agents and Pandemic influenza
$1,843,086Kelly J. Henrickson · Medical College Of Wisconsin · U01 · FY2009 · AI
Origin and maturation of protective memory B cell responses against pathogenic viruses in natural infections and upon vaccination.
$1,841,725Mattia Bonsignori · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Influenza and Emerging Infectious Diseases
$1,840,538Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Idaho Biomedical Research Collaborative in Emerging/Reemerging Infectious Disease
$1,837,517Dennis L Stevens · Idaho Veterans Research / Education Fdn · P20 · FY2016 · GM
Emerging Infectious Diseases Research Center - East and Central Africa
$1,836,448M Kariuki Njenga · Washington State University · U01 · FY2024 · AI
Genetic and Structural Basis for Virus Neutralization of Paramyxoviruses
$1,835,755Vanderbilt University Medical Center · N01 · FY2025 · AI
Thymic vaccination: Manipulating the T cell repertoire
$1,834,795Dana-Farber Cancer Institute · R01 · FY2003 · AI
Adjuvant Enhanced Antiviral Immunity
$1,829,840Jeff C Fairman · Juvaris Biotherapeutics, Inc. · U01 · FY2010 · AI
Toward a Universal Influenza Virus Vaccine
$1,829,781Peter Palese · Icahn School Of Medicine At Mount Sinai · P01 · FY2022 · AI
Development/production of universal influenza vaccines
$1,829,600Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2010 · AI
Development/production of universal influenza vaccines
$1,829,600Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2011 · AI
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
$1,827,379Jennifer Lapek · Scripps Institution Of Oceanography · N01 · FY2025 · AI
Clinical Studies of Vaccines for Pandemic Influenza
$1,826,779Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
PROTECTIVE AND DAMAGING LYMPHOCYTE RESPONSES IN THE LUNG
$1,823,004Trudeau Institute, Inc. · P01 · FY2004 · HL
CEIRS Influenza Data Processing and Coordinating Center (DPCC)
$1,820,913Gillian Air · Digital Infuzion, Inc. · N01 · FY2014 · AI
Host-pathogen competition in IFN mediated antiviral defense
$1,820,077Jae U Jung · University Of Southern California · U19 · FY2013 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$1,818,913Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2022 · AI
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES
$1,818,454Tyson Heilherker · Boston Children'S Hospital · N01 · FY2023 · AI
Toward a Universal Influenza Virus Vaccine
$1,816,495Peter Palese · Icahn School Of Medicine At Mount Sinai · P01 · FY2021 · AI